PETROSCRAP.COM

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer
Amgen today announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer. The results are being presented for the first time in an oral presentation at the 2010 American Society of Clinical Oncology Annual Meeting.

Read more on News-Medical-Net

This entry was posted on Wednesday, June 9th, 2010 at 9:35 am and is filed under Polymer News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.